A Phase 1 interventional study of PA32540 and aspirin component of PA32540 in Healthy, sponsored by POZEN. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-03-10.
Sponsored by POZEN · Phase 1 and Interventional
Study to determine a single dose bioavailablity of PA32540 is similar to EC aspirin 325 mg with respect to salicylic acid.
POZEN is the lead sponsor of 26 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Single oral dose of 325 mg aspirin administered as PA32540
Drug: PA32540
aspirin core
Drug: aspirin component of PA32540
active
Drug: Ecotrin
The 325 mg aspirin component of PA32540
325 mg Ecotrin
No study locations are listed for this record.
This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
POZEN